Medikament�se Behandlung prim�rer Hyperlipoprotein�mien

Abstract

Cardiovascular disease has become the major cause of death in the Western countries. There is strong evidence that elevations of serum lipids contribute to the pathogenesis of premature atherosclerosis. The classification of the hyperlipoproteinemias has been most beneficial as a guide to development of dietary and pharmacological regimens for lowering serum lipid concentrations. The results of dietary and drug prevention trials are discussed. Insight into the mechanisms involved in lipoprotein metabolism as well as the mode of action and of side-effects of hypolipidemic drugs is reviewed. Using present knowledge of heart disease research, it is reasonable to suggest dietary and drug treatments for the high risk patient.

Zusammenh�nge zwischen Serum-Lipoproteinstoffwechsel und bili�rem Lipidstoffwechsel

“…Es senkt Triglyceride und VLDL stfirker als Cholesterin und LDL [11,12,14,95,200]. die Typen II B, III, IV und V geeignet.…”